- World Pharma News Home » Product » Federal Court of Appeal in Canada Upholds Lipitor Enantiomer Patent
(a free service delivered by FeedBurner)
Pfizer Inc said today that the Federal Court of Appeal of Canada has reversed a lower court ruling that held that Pfizer's enantiomer patent could not block generic manufacturer Ranbaxy Laboratories Limited from obtaining approval for a competitor product to Lipitor. The appellate court issued an order prohibiting regulatory approval of Ranbaxy's product in Canada until Pfizer's enantiomer (calcium salt) patent - Canadian Patent No. 2,021,546 - expires in July 2010.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments